CAR T cell therapy tested in young people with lupus

Trial details

Who runs it

Children's Hospital of Philadelphia

Trial code

NCT06839976

Record updated

24 September 2026

Original description

This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE).Read full original descriptionShow less

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)

This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE).

Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.

Inclusion: Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window; Patient age must be 10-29 years, inclusive, at time of enrollment; Meeting ACR/EULAR Classification Criteria for SLE; ANA positive > 1:80 and/or double-stranded DNA (dsDNA) positive; Active (refractory) disease, defined as follows:; Lupus nephritis subjects must meet both the following criteria: i. ISN/RPS active nephritis Class III/IV +/- V lupus nephritis diagnosed by biopsy within past 12 months; Persistent and clinically significant: ≥2 measurements with urine protein with either of the following:; > 1mg/mg creatinine; > 0.5 mg/mg creatinine associated with renal dysfunction or low albumin; > 0.5 mg/mg creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg/day or 0.15mg/kg/day, whichever is lower, due to active disease; Patients must have had at least 3 months of cumulative conventional therapy defined as:; Conventional induction immunosuppressive agent(s) (e.g., mycophenolate mofetil, cyclophosphamide), and; At least one additional therapy:; B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor) 7. Adequate organ function status; Renal: eGFR must be ≥30 and subject cannot be receiving dialysis; Hepatic: Transaminases < 5x upper limit of normal and serum conjugated (Direct) bilirubin <1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C; Cardiac: Shortening fraction > 28%, left ventricular ejection fraction >45%, and no evidence of severe pulmonary hypertension; Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and <Grade 3 hypoxia; DLCO ≥40% (corrected for anemia and/or VA volume if necessary) if PFTs are clinically appropriate as determined by the treating investigator; Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion: Previous autologous or allogenic stem cell transplant; Previous kidney transplant; Patients who are on anti-epileptic therapy; Participation in a clinical trial in which the patient receives an investigational drug within a time period equal or less than 5.5 half-lives of the investigational agent prior to study enrollment; Subjects who are unwilling or unable to discontinue immunosuppressive medications at the times of CART19 infusion will be excluded from the trial; Any comorbidity that in the opinion of the investigators would jeopardize the ability of the subject to tolerate therapy; Active, untreated infections; HIV infection; Active Hepatitis B; Patients must have a negative hepatitis B surface antigen to be enrolled on this study; Active Hepatitis C; Patients with severe neuropsychiatric lupus or neurologic manifestations of SLE (e.g. stroke, seizure, psychosis, demyelinating syndromes, organic brain syndrome, or lupus related headaches); History of seizure disorder; Monogenic lupus (known); Pregnant patients. All participants of childbearing potential must have negative pregnancy test; Lactating participants who want to continue breastfeeding; Patients who are unwilling to consent to LTFU.

ClinicalTrials.gov NCT06839976